NEW YORK (GenomeWeb) — Finnish diagnostics firm Mobidiag said today that it received CE-IVD marking for its Novodiag CarbaR+ test for carbapenemase-producing enterobacteriaceae (CPE), a bacteria resistant to carbapenem antibiotics.
The multiplex qPCR- and microarray-based test detects CPE and associated resistance markers, as well as a plasmid-mediated resistance for colistin, a last-resort antibiotic for many infections. It runs on the company's automated Novodiag system and produces results within 80 minutes.
Mobidiag currently offers two other CE-marked antibiotic resistance screening tests including CarbaR+VRE and CarbaR+MCR, which run on the firm's Amplidiag multiplex system.
"With our Amplidiag and Novodiag tests, we offer comprehensive diagnostic solutions to a wide range of infectious diseases in both centralized and decentralized laboratories, regardless of their size and patient volumes," Mobidiag CEO Tuomas Tenkanen said in a statement.